New treatments for cancer using human-specific STING activators
Official title: Human specific STING agonists for the treatment of cancer
Funded at Stinginn, LLC · NIH-10759593 · Data updated 2026-11-12
This study is looking at a new way to help your immune system fight cancer by using special drugs that can be taken by mouth, making it easier for patients to access treatment and potentially improve how well it works against different types of cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stinginn, LLC NIH-funded |
| Lab location | 1 site (Miami, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $399,812 |
| NIH project number | 1R41CA275637-01A1 |
| Project ID | NIH-10759593 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with various types of cancer who are seeking innovative treatment options.
✕Less likely to help
Patients with non-malignant conditions or those who do not have a cancer diagnosis may not benefit from this research.
What this research studies
This research investigates the use of human-specific STING agonists to enhance the body's immune response against cancer. By activating the STING pathway, the treatment aims to stimulate the production of immune cells that can target and destroy tumors. The approach focuses on developing oral drug delivery methods to make the treatment more accessible and effective for patients. The research will explore how these agonists can be administered and their potential impact on various types of cancers.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the body's own immune system to fight tumors.
How similar studies have gone: Other research has shown promising results with similar immune-activating approaches, indicating potential for success in this area.
Where this research is happening
-
Stinginn, LLC
Miami, United States Active
Researchers
- Principal investigator: Barber, Glen N — Stinginn, LLC
- Study coordinator: Barber, Glen N
Related research
Other NIH-funded projects on the same topics.
-
Developing a vaccine to prevent diseases caused by the Human T Cell Lymphotropic Virus
This study is testing a new vaccine to help prevent and treat serious health issues linked to the HTLV-1 virus, like adult T cell leukemia and a nerve condition called HAM/TSP, and it's for people who might be at risk of getting this virus.
-
Using STING activators to enhance cancer treatment
This study is looking at a new way to help your immune system fight aggressive leukemia by using a special treatment that activates a protein called STING, and it’s designed for patients whose leukemia has come back or hasn’t responded to other treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.